TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06236243

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng Extract Powder 120 mg/tablet
Description: Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng Extract Powder 500 mg/tablet
Description: Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
Study: NCT06533423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newly diagnosed with Inflammatory arthritis - a Self-MAnagement intervention (NISMA)
Description: The NISMA intervention is a flexible intervention and comprises three mandatory individual sessions with a nurse, supplemented by two optional group sessions over a period of 12 months, to provide comprehensive support tailored to each participant's needs. The intervention is grounded in the theoretical framework Social Cognitive Theory and inspired by the questioning techniques in Acceptance and Commitment Therapy (ACT). These methods play a crucial role in helping participants enhance their self-efficacy. The key components of our approach include: a person-centered approach by addressing challenges identified by each participant to foster self-efficacy through targeted problem-solving and goal-setting. This is utilized by interviewing techniques derived from ACT to assist participants in accepting and committing to self-management. The program is designed to last between 6-12 months, allowing for gradual skill development and adaptation.
Study: NCT06340178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid application during ct-guided lung biopsy
Description: Injection of a small amount of fluid (max. 20 ml sodium chlorid) in the pleural cavity at the biopsy site
Study: NCT05862727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth Intervention
Description: Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
Study: NCT06551142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5764227
Description: GSK5764227 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5764227
Description: GSK5764227 will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered
Study: NCT05240534

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ET-Text (Laptop)
Description: ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ET-Voice (Smart System)
Description: ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience.
Study: NCT05765812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered as capsules.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
Study: NCT05062200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral tablet.
Study: NCT06552364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA+LAMA
Description: 1 dose per day (AM)
Study: NCT05062200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral tablet.
Study: NCT06552364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LABA+LAMA
Description: 1 dose per day (AM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA+LAMA+ICS
Description: 1 dose per day (AM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA+LAMA+ICS
Description: 1 dose per day (AM)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air
Description: Exposure to HEPA filtered air, as a control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air
Description: Exposure to HEPA filtered air, as a control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel Exhaust
Description: Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Study: NCT06654258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spiritual Self-Care Smartphone App
Description: Participants will be asked to engage with a commercially available spiritual self-care smartphone app on a daily basis for 6 weeks. The content spans several domains, including meditation, prayer, affirmations, movement (i.e., stretching and yoga), and music. The user experience is highly personalized, allowing the user to select content that matches their current: mood or needs (e.g., anxiety, loneliness, stress, self-esteem, and sleep), time of day (e.g., recommendations for morning and evening practices), and/or availability (e.g., very brief micro-interventions lasting no more than 90 seconds or longer activities up to 30 minutes in duration). The content is delivered via a combination of audio and visual modalities on a personal smartphone that can be toggled on and off to adjust to surroundings.
Study: NCT05881460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active vibrotactile coordinated reset
Description: Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibrotactile coordinated reset
Description: Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
Study: NCT06659679

Intervention type: DRUG
Intervention: New use of oral semaglutide
Description: New use of oral semaglutide dispensing claim is used as the exposure.

Intervention type: DRUG
Intervention: New initiation of sitagliptin
Description: New use of sitagliptin dispensing claim is used as the reference.
Study: NCT06659627

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic exercise therapy
Description: Participants will follow an aerobic exercise therapy program for 16 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioural therapy
Description: Participants will follow an cognitive behavioural therapy program for 12-16 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants do not follow a program, but continue with care as usual
Study: NCT06659263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE104 for Injection
Description: Single, subcutaneous dose of RE104 for Injection
Study: NCT03901534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Standard, clinically used CPAP therapy. CPAP will be prescribed by the participants' clinician provider and not by the study investigators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nox A1 Recorder
Description: Non-invasive, body-worn, sleep recording device for nocturnal polysomnography.
Study: NCT06660433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care respiratory test platform
Description: A point-of-care respiratory multiplex testing platform situated within a long-term care facility to provide rapid test results
Study: NCT04931680

Intervention type: OTHER
Intervention: Data collection
Description: During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.

Intervention type: OTHER
Intervention: Data collection
Description: During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
Study: NCT04744662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Ophthalmic solution
Description: Liquid formulation administered by intravitreal (IVT) injection
Study: NCT06660433

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Existing respiratory virus testing platform
Description: Currently used respiratory virus testing platforms
Study: NCT06608472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N0877
Description: 1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benicar HCT ® Tablets 40 mg/25 mg
Description: 1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877
Study: NCT06591286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: This group of patients will wear RT-CGM for blood glucose monitoring for three months.

Intervention type: DEVICE
Group type: OTHER
Intervention: SMBG
Description: This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.
Study: NCT06532383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-07940369
Description: Bulk powder for extemporaneous preparation for oral solutions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bulk powder for extemporaneous preparation for oral solutions
Study: NCT06462716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BY101298 Capsules
Description: An oral DNA-PK Inhibitor
Study: NCT06532383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bulk powder for extemporaneous preparation for oral solutions
Study: NCT06608368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (Sensodyne Repair and Protect Original Mint)
Description: Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control Dentifrice (Sensodyne Fresh Mint)
Description: Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Dentifrice (Crest Cavity Protection Regular)
Description: Dentifrice containing 1100 ppm fluoride as sodium fluoride.
Study: NCT06587308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dorsal-Double-Layered 10% Circumferential Reduction (DD-10) Pressure Garment
Description: During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the DD-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-Layered 10% Circumferential Reduction (S-10) Pressure Garment
Description: During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Single-Layered No Circumferential Reduction (S-0) Pressure Garment
Description: During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-0 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
Study: NCT06047301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways
Description: Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
Study: NCT05220631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology intervention
Description: Older Adult Technology Services (OATS) 5-week technology intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology intervention
Description: Older Adult Technology Services (OATS) 5-week technology intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Nutrition Intervention
Description: 15-week nutrition intervention delivered completely online

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Nutrition Intervention
Description: 15-week nutrition intervention delivered completely online
Study: NCT05184478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.
Description: Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.
Description: Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase.
Study: NCT05891561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 4 cycles of taxane, pertuzumab, trastuzumab
Study: NCT06546826

Intervention type: PROCEDURE
Intervention: BARP
Description: deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer

Intervention type: PROCEDURE
Intervention: simple tooth extraction
Description: tooth extraction without grafting procedure.

Intervention type: PROCEDURE
Intervention: tooth root and PRF
Description: Autogenous roots derived from the extracted hopeless tooth and stabilized with osteosynthesis screws to reconstruct the missing buccal wall of the socket. The defect was then filled with PRF.

Intervention type: PROCEDURE
Intervention: Ice cream cone technique
Description: xenogeneic granules and a resorbable collagen membrane
Study: NCT06621914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR 80
Description: The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BFR40
Description: The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 40% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.